References for health-related quality-of-life claims in prescription drug advertisements

American Journal of Health-System Pharmacy

Volumn 54, Issue 22, 1997, Pages 2596-2599

  Rothermich, Elizabeth A ^a   Pathak, Dev S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; ARTICLE; DRUG MARKETING; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0030727320     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.22.2596     Document Type: Article

References (34)

1. Szeinbach LS, Juergens JP, Smith MC et al. Content analysis of pharmacoeconomic appeals in pharmaceutical drug product advertisements. /Res Pharm Econ. 1991; 3(3):75-90.
2. Rothermich EA, Pathak DS, Smeenk DA. Health-related quality-of-life claims in prescription drug advertisements. Am J Health-Syst Pharm. 1996; 53:1565-9.
3. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994; 272:619-26.
4. Pathak DS, MacKeigan LD. Assessment of quality of life and health status: selected observations. / Res Pharm Econ. 1992; 4(4):31-51.
5. Giovanni FA, Magnani B. Quality of life: a review of contemporary confusion. Med Sei Res. 1988; 16:1051-4.
6. MacKeigan LD, Pathak DS. Overview of health-related quality-of-life measures. Am J Hasp Pharm. 1992; 49:2236-45.
7. Kassarjian HH. Content analysis in consumer research. / Consum Res. 1977; 4:8-18.
8. Kolbe RH, Burnett MS. Content-analysis research: an examination of applications with directive for improving research reliability and objectivity. / Consum Res. 1991; 18:243-50.
9. Penick TM, Smith MC. Content analysis of appeals used in advertising in the American Journal of Hospital Pharmacy in 1960, 1970, 1980, and 1990. Paper presented at ASHP Midyear Clinical Meeting. Orlando, FL; 1992 Dec 9.
10. Perrault WD Jr, Leigh LE. Reliability of nominal data based on qualitative judgments. / Mark Res. 1989; 26:135-48.
11. Goldberg HL, Finnerty RJ. The use of doxepin in the treatment of symptoms of anxiety neurosis and accompanying depression: a collaborative controlled study. Am J Psychiatry. 1972; 129(l):74-7.
12. Feighner JP. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. / Clin Psychiatry. 1985; 46:369-72.
13. Byerley WF, Reimherr FW, Wood DR et al. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. / Clin Psychopharmacol. 1988; 8(2):112-5.
14. Karacan 1, Blackburn AB, Thornby Jl et al. The effect of doxepin HC1 (Sinequan) on sleep patterns and clinical symptomatology of neurotic depressed patients with sleep disturbance. In: Mendels J, ed. Sinequan (doxepin HC1). Amsterdam, Netherlands: Excerpta Medica; 1975:4-22.
15. Reimherr FW, Chouinard G, Conn CK et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitrip-tyline-controlled, multicenter comparison study in outpatients with major depression. / Clin Psychiatry. 1990; 51(12, supplB): 18-27.
16. Doogan DP, Gaillard V. Sertraline in the prevention of depression. Br J Psychiatry. 1992; 160:217-22.
17. Ballenger JC, Burrows GD, DuPont RL Jr et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry. 1988; 45:413-22.
18. Clarke CH, Nicholson AN. Performance studies with antihistamines. Br J Clin Pharmacol. 1978; 6:31-5.
19. Nicholson AN, Stone BM. Antihistamines: impaired performance and the tendency to sleep. EurJ Clin Pharmacol. 1986; 30:27-32.
20. Nicholson AN, Stone BM. The Hl-antagonist mequitazine: studies on performance and visual function. Eur / Clin Pharmacol. 1983; 25:563-6.
21. Nicholson AN, Stone BM. Performance studies with the Hr histamine receptor antagonists, astemizole and terfenadine. Br J Clin Pharmacol. 1982; 13:199-202.
22. Swire FMM, Marsden CA, Birmingham AT. Effects of a sedative and of a non-sedative H,-antihistamine on the eventrelated potential (ERP) in normal volunteers. Psychopharmacology. 1989; 98:425-9.
23. Nicholson AN, Smith PA, Spencer MB. Antihistamines and visual function: studies on dynamic acuity and the pupillary response to light. BrJClin Pharmacol. 1982; 14:683-90.
24. Fink M, Irwin P. CNS effects of the antihistamines diphenhydramine and terfenadine (RMI9918). Pharmakopsychiatr Neuropsychopharmakol. 1979; 12:35-44.
25. Kulshrestha VK, Gupta PP, Turner P et al. Some clinical pharmacological studies with terfenadine, a new antihistamine drug. Br I Clin Pharmacol. 1978; 6:25-9.
26. Moser L, Huther KJ, Koch-Weser J et al. Effects of terfenadine and diphenhydramine alone or in combination with diazepam or alcohol on psychomotor performance and subjective feelings. Eur J Clin Pharmacol. 1978; 14:417-23.
27. Luscombe DK, Nicholls PJ, Parish PA. Comparison of the effects of azatadine maleate and terfenadine on human performance. Pharmacotherapeutica. 1983; 3:370-5.
28. Roehrs TA, Tietz El, Zorick FJ et al. Daytime sleepiness and antihistamines. Sleep. 1984; 7(2):137-41.
29. Georgotas A, McCue RE, Cooper TB et al. How effective and safe is continuation therapy in elderly depressed patients? Arch Gen Psychiatry. 1988; 45:929-32.
30. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 1988; 259:539-44.
31. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. I Am Coll Cardiol. 1983; 2:755-63.
32. Wilkes MS, Doblin BS, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med. 1992; 116:912-9.
33. PDA, Division of Drug Marketing, Advertising and Communications. Principles for the review of pharmacoeconomic promotion. Draft guidelines. Rockville, MD: U.S. Department of Health and Human Services; 1995.
34. Quality of life ad claims should be specific, PDA-sponsored physician focus groups say; ad division director cautions against QoL "claim expansiveness." FDC Rep. 1994; 56(4):8-9.